Corporate / M&A

Regulatory

Employment and Executive Compensation

Healthcare / Life Sciences

novo-nordisk_web_640x140

Homburger News

Share-Image Teamplate Deals-and-Cases

On December 18, 2024, Novo Nordisk announced that it has successfully completed its USD 11 bn acquisition of three manufacturing sites from Novo Holdings A/S. The completion follows the finalization of Novo Holdings&#8250; acquisition of Catalent, Inc., a global contract development and manufacturing organization. The three acquired sites are specialized in the sterile filling of drugs and are located in Anagni (Italy), Brussels (Belgium) and Bloomington IN (USA).
Novo Nordisk is a leading global healthcare company headquartered in Denmark. Its purpose is to drive change to defeat serious chronic diseases, built upon its heritage in diabetes.
Catalent is a global contract development and manufacturing organization headquartered in Somerset, New Jersey. The company has over 50 global sites and employs more than 18,000 people.
A Homburger team comprising Andreas Müller, Anna Peter, Simone Schmid, Bianca Nedwed, Florian Bruggisser and Maria Braun (all Corporate / M&amp;A), Allegra Arnold, Meret Horisberger and Harun Cetin (all Regulatory), Jeremy Reichlin (Employment) as well as Reto Heuberger, Juliette Buob and Philipp Stiegeler (all Tax) advised Novo Nordisk on the transaction.

Homburger advises on Novo Nordisk / Novo Holdings / Catalent transaction

Litigation

Financial Market Regulation

On December 2, 2024, Bank J. Safra Sarasin AG announced the acquisition of 100% of the shares of MIV Asset Management AG («MIV»).
MIV is characterized through its investments in medical technology and its flagship fund, the MIV Global Medtech Fund. MIV is known for its innovative approach and in-depth knowledge of the sector. MIV&#8217;s offering is an addition to Bank J. Safra Sarasin&#8217;s range of thematic equity strategies, which are available to both private and institutional investors.
MIV&#8217;s investment strategy and organizational structure will remain unchanged to ensure solid performance and seamless client service.
The Homburger team advising the selling shareholders was led by Daniel Hasler and Daniel Daeniker and included Stefan Blunschi, Caspar Wehrle, Bianca Nedwed and Felix Beltle (all Corporate / M&amp;A), Marc Bircher (Litigation), Jürg Frick and Philipp Klein (both Financial Market Regulation), Stefan Oesterhelt, Peter Müller and Philipp Stiegeler (all Tax) as well as Jeremy Reichlin (Employment and Executive Compensation).

Homburger advised the shareholders of MIV Asset Management AG on the sale of 100% of their shares to Bank J. Safra Sarasin AG  

Homburger advised the Kellenberger family on the reduction of its shareholding in Calida Holding AG

The Kellenberger family has significantly reduced its shareholding in Calida Holding AG (the Company) in two transactions, a public buy-back offer and a direct repurchase.
Homburger advised the Kellenberger family on these transactions.
The Homburger team was led by Dieter Gericke and included Hansjürg Appenzeller, Daniel Häusermann, Cédric Berger, Thierry Burckhardt, Caspar Wehrle and Marc Abplanalp (all Corporate / M&amp;A) as well as Reto Heuberger, Arbnor Sheholli and Philipp Stiegeler (all Tax).

Philipp
Stiegeler

Homburger advises on Novo Nordisk / Novo Holdings / Catalent transaction

Homburger advised the shareholders of MIV Asset Management AG on the sale of 100% of their shares to Bank J. Safra Sarasin AG

Homburger advised the Kellenberger family on the reduction of its shareholding in Calida Holding AG

Join the Team

Philipp Stiegeler

Career

Languages

Bar Registration

Teams